Zepbound for Weight Loss: How It Works, Dosing, and What to Expect

Last updated: May 15, 2026

## TLDR

– Zepbound is FDA-approved tirzepatide (manufactured by Eli Lilly) for chronic weight management.
– It is the first dual GIP + GLP-1 receptor agonist approved for weight loss — a meaningfully different mechanism from semaglutide-only options.
– The SURMOUNT-1 Phase 3 trial showed up to 20.9% average body weight reduction at the 15 mg maintenance dose.
– Dosing starts at 2.5 mg/week and escalates to a maintenance dose of 5, 10, or 15 mg/week.
– Side effects are mostly gastrointestinal and most pronounced during dose escalation.
– Head-to-head data shows Zepbound outperforms Wegovy for weight loss.
– Licensed providers on Klarity Health can evaluate and prescribe Zepbound entirely online.

—

## Table of Contents

– [What Is Zepbound?](#what-is-zepbound)
– [How Zepbound Works: The Dual-Agonist Difference](#how-zepbound-works-the-dual-agonist-difference)
– [Zepbound Dosing Schedule](#zepbound-dosing-schedule)
– [Expected Weight Loss Results](#expected-weight-loss-results)
– [Zepbound Side Effects](#zepbound-side-effects)
– [Zepbound vs. Wegovy and Ozempic](#zepbound-vs-wegovy-and-ozempic)
– [Zepbound Cost and Insurance](#zepbound-cost-and-insurance)
– [How to Get a Zepbound Prescription](#how-to-get-a-zepbound-prescription)
– [Frequently Asked Questions](#frequently-asked-questions)

—

## What Is Zepbound?

Zepbound is the brand name for tirzepatide manufactured by Eli Lilly and Company. It is a once-weekly injectable medication FDA-approved in November 2023 for chronic weight management in adults with:

– A BMI of **30 or higher** (obesity), or
– A BMI of **27 or higher** (overweight) with at least one weight-related complication, such as type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnea.

In June 2024, the FDA also approved Zepbound for the treatment of **moderate-to-severe obstructive sleep apnea (OSA)** in adults with obesity — the first prescription medication approved for that indication.

As of 2025, Zepbound ranks as the **#1 prescribed medication in the obesity management medication class**, according to IQVIA NPA data. Its once-weekly dosing, strong clinical efficacy, and growing awareness of dual agonism have made it one of the most sought-after weight loss treatments available.

**[Talk to a licensed provider about Zepbound — entirely online →](https://www.helloklarity.com/service/weight-loss)**

—

## How Zepbound Works: The Dual-Agonist Difference

To understand what separates Zepbound from other weight loss injections, you need to understand the two hormones it targets.

### GLP-1 (Glucagon-Like Peptide-1)

GLP-1 is a gut hormone released after eating. It signals the pancreas to release insulin, suppresses glucagon (which raises blood sugar), slows gastric emptying, and sends satiety signals to the brain. Together, these effects reduce appetite and caloric intake. Semaglutide (Ozempic, Wegovy) works by targeting GLP-1 receptors alone.

### GIP (Glucose-Dependent Insulinotropic Polypeptide)

GIP is a second gut hormone released in response to food. It also stimulates insulin release and, in the context of weight management, is thought to enhance the appetite-suppressing effects of GLP-1 activation. GIP receptor activity may also play a role in reducing GI side effects compared to GLP-1 agonism alone.

### The Dual-Agonist Advantage

Zepbound activates both GIP and GLP-1 receptors simultaneously. This synergistic mechanism produces:

– **Greater appetite suppression** than GLP-1 agonism alone
– **Stronger metabolic effects** on insulin sensitivity and fat utilization
– **Superior weight loss outcomes** compared to semaglutide in head-to-head clinical data

This is the mechanistic reason SURMOUNT-1 data outpaces the STEP-1 results from Wegovy — it is not a dose difference, it is a fundamentally different pharmacological action ([NEJM SURMOUNT-1 Trial](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038)).

—

## Zepbound Dosing Schedule

Zepbound is administered as a subcutaneous injection once weekly, using the Lilly KwikPen® auto-injector. Approved injection sites are the abdomen, thigh, or upper arm.

### Standard Dose Escalation

| Weeks | Dose |
|—|—|
| 1–4 | 2.5 mg once weekly (start dose only — not a maintenance dose) |
| 5–8 | 5 mg once weekly |
| 9–12 | 5 mg or increase to 7.5 mg if tolerated |
| 13–16 | Continue or increase to 10 mg |
| 17–20 | Continue or increase to 12.5 mg |
| 21+ | Continue or increase to 15 mg maximum |

**Maintenance doses for weight loss:** 5 mg, 10 mg, or 15 mg once weekly.
**Maintenance doses for obstructive sleep apnea:** 10 mg or 15 mg only.
**Maximum approved dose:** 15 mg once weekly.
**Maximum escalation rate:** No more than 2.5 mg increase every 4 weeks.

The goal is to reach the highest dose your body tolerates well — not to rush to maximum dose. If GI side effects are significant at any step, your provider may slow escalation and keep you at the current dose for 8 weeks instead of 4. There is no clinical evidence that faster escalation produces better outcomes; tolerability is the priority.

Zepbound is used alongside a reduced-calorie diet and increased physical activity. It is not a standalone solution — it works best as one component of a structured weight management plan.

—

## Expected Weight Loss Results

The pivotal efficacy data comes from the SURMOUNT-1 trial: a 72-week double-blind, randomized, placebo-controlled Phase 3 study of 2,539 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related complication, excluding type 2 diabetes ([NEJM, 2022](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038)).

### SURMOUNT-1 Average Body Weight Reduction

| Dose | Average % Weight Reduction | Placebo |
|—|—|—|
| 5 mg/week | ~15.0% | ~3.1% |
| 10 mg/week | ~19.5% | ~3.1% |
| 15 mg/week | ~20.9% | ~3.1% |

To put 20.9% in context: for a 250-pound person, that is approximately **52 pounds of weight reduction** over 72 weeks.

Responder rates at the 15 mg dose:

– ~91% of participants lost at least **5% of body weight**
– ~57% of participants lost at least **20% of body weight**

**One important caveat:** These are on-treatment results. Weight regain after stopping Zepbound is common and well-documented. In the SURMOUNT-4 trial, participants who stopped tirzepatide after 36 weeks regained approximately two-thirds of their lost weight over the following 52 weeks. Zepbound is designed as a long-term treatment, not a short course.

—

## Zepbound Side Effects

Like all GLP-1 class medications, Zepbound’s most common side effects are gastrointestinal. These effects are most pronounced during dose escalation and generally improve substantially over time.

### Common Side Effects

– **Nausea** (most common)
– Diarrhea
– Constipation
– Vomiting
– Abdominal discomfort or pain
– Indigestion (dyspepsia)
– Decreased appetite (often a desired effect)

**Strategies to reduce GI side effects:**

– Eat smaller, lower-fat meals — especially around injection day
– Stay well hydrated; avoid alcohol in the first 24–48 hours post-injection
– Avoid fried, spicy, or heavily processed foods during the first weeks
– Inject on a day when the following day’s schedule is lighter
– Ask your provider about slowing the escalation schedule if symptoms are severe

### Serious Warnings

Zepbound carries a **boxed warning** for thyroid C-cell tumors, observed in animal studies. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).

Additional serious risks include pancreatitis, gallbladder disease, hypoglycemia (particularly when combined with insulin or sulfonylureas), and acute kidney injury from dehydration secondary to GI side effects.

A complete medical and family history review by a licensed provider is necessary before starting Zepbound.

—

## Zepbound vs. Wegovy and Ozempic

Zepbound, Wegovy, and Ozempic are the dominant prescription options in the GLP-1 weight loss category. Here is how they compare:

| | Zepbound | Wegovy | Ozempic |
|—|—|—|—|
| Drug | Tirzepatide | Semaglutide | Semaglutide |
| Manufacturer | Eli Lilly | Novo Nordisk | Novo Nordisk |
| Mechanism | Dual GIP + GLP-1 | GLP-1 only | GLP-1 only |
| FDA indication | Weight loss, sleep apnea | Weight loss | Type 2 diabetes (weight loss off-label) |
| Maximum dose | 15 mg/week | 2.4 mg/week | 2 mg/week |
| Avg weight loss (Phase 3) | ~20.9% at highest dose | ~14.9% (STEP-1) | ~15% (varies) |
| Dosing | Once weekly | Once weekly | Once weekly |

In the SURMOUNT-5 head-to-head trial (published 2025), tirzepatide demonstrated **statistically superior weight loss** compared to semaglutide 2.4 mg, with participants losing approximately 47% more weight on tirzepatide on average. This positions Zepbound as the more potent option for weight management among currently approved therapies.

**Ozempic** contains the same molecule as Wegovy (semaglutide) but is FDA-approved for type 2 diabetes, not weight loss. It is widely prescribed off-label for weight management, though Wegovy is the formally approved weight-loss-labeled version.

—

## Zepbound Cost and Insurance

### List Price

Zepbound’s list price is approximately **$1,059 per month** (4-week supply) without insurance or savings programs.

### Lilly Savings Program

Eli Lilly offers a savings card that can reduce out-of-pocket cost to **as low as $25 per prescription** for eligible commercially insured patients. Details at [LillyDirect](https://www.lillydirect.com/zepbound/).

### Insurance Coverage

Commercial insurance coverage varies. Many plans require:

– Documented BMI ≥30, or ≥27 with a qualifying comorbidity
– Prior authorization from your provider
– Evidence of prior weight management attempts

Medicare Part D largely excludes weight loss medications as of mid-2025, though legislative changes remain active. A licensed provider can assist with prior authorization documentation to support coverage requests.

—

## How to Get a Zepbound Prescription

Zepbound requires a prescription from a licensed provider. The traditional route — in-person GP visit, specialist referral, weeks of waiting — is no longer the only option.

Klarity Health is a telehealth platform with **2,000+ licensed providers** who offer weight loss consultations entirely online. A licensed provider on Klarity Health can:

– Review your medical history, BMI, and relevant comorbidities
– Determine whether Zepbound or another GLP-1/dual agonist is appropriate for you
– Provide a prescription if clinically indicated
– Support prior authorization requests for insurance coverage

The entire process is online. Appointments are typically available within days, and there are no referral requirements or specialist wait times.

**[See if Zepbound is right for you — consult a licensed provider on Klarity Health →](https://www.helloklarity.com/service/weight-loss)**

—

## Frequently Asked Questions

### Is Zepbound the same as Mounjaro?

Both Zepbound and Mounjaro contain tirzepatide (manufactured by Eli Lilly). The difference is their FDA-approved indications: Mounjaro is approved for type 2 diabetes management, while Zepbound is approved specifically for chronic weight management and obstructive sleep apnea. The drug molecule and mechanism are identical.

### How quickly does Zepbound start working?

Most patients notice reduced appetite within the first 1–2 weeks. Measurable weight loss typically begins in weeks 4–8. The most substantial reductions accumulate over the full 72-week treatment period. The 2.5 mg starting dose is not a therapeutic maintenance dose — meaningful efficacy builds as you escalate toward 5, 10, or 15 mg.

### How long do you stay on Zepbound?

Zepbound is designed as a long-term medication, not a short course. Clinical trials ran for 72 weeks, and evidence consistently shows weight regain after discontinuation. Most clinicians approach it similarly to blood pressure medication — an ongoing treatment continued as long as it is effective and tolerated.

### Can you stop Zepbound and keep the weight off?

Research is consistent: most patients regain substantial weight after stopping. SURMOUNT-4 showed approximately two-thirds of lost weight returned within 52 weeks of discontinuation. Behavioral changes established during treatment (improved diet, increased activity, better sleep) reduce but do not eliminate regain risk.

### Is Zepbound covered by insurance?

Coverage varies significantly by plan. Many commercial plans cover it with prior authorization. Medicare Part D generally does not as of 2025. Lilly’s savings program can substantially reduce out-of-pocket cost for those with commercial insurance.

### Who should not take Zepbound?

Zepbound is contraindicated for people with a personal or family history of medullary thyroid carcinoma or MEN2, those who are pregnant or planning pregnancy, and those with severe GI disorders. A licensed provider will review your full history before prescribing.

—

## Conclusion

Zepbound (tirzepatide) represents a meaningful advance in prescription weight management. Its dual GIP and GLP-1 mechanism produces greater appetite suppression and more substantial weight reduction than earlier GLP-1-only therapies — with SURMOUNT-1 data showing up to 20.9% average body weight loss at the highest dose, and head-to-head trials confirming superiority over Wegovy.

For adults with a BMI of 30+ (or 27+ with a weight-related condition), Zepbound is worth serious consideration as part of a comprehensive weight management plan that includes dietary changes and physical activity.

Licensed providers on Klarity Health can evaluate you online, walk you through whether Zepbound is the right fit, and prescribe if clinically appropriate. With 2,000+ providers and no in-person visit required, getting started is straightforward.

**[Start your Zepbound consultation with a licensed provider on Klarity Health →](https://www.helloklarity.com/service/weight-loss)**

—

*Sources: [NEJM SURMOUNT-1 Trial (2022)](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038) | [FDA Zepbound Prescribing Information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf) | [LillyDirect Zepbound](https://www.lillydirect.com/zepbound/) | [IQVIA NPA Data](https://www.iqvia.com/)*